JP2018502068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502068A5 JP2018502068A5 JP2017530141A JP2017530141A JP2018502068A5 JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5 JP 2017530141 A JP2017530141 A JP 2017530141A JP 2017530141 A JP2017530141 A JP 2017530141A JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fusion protein
- condition
- high affinity
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Division JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502068A JP2018502068A (ja) | 2018-01-25 |
| JP2018502068A5 true JP2018502068A5 (enExample) | 2018-12-13 |
| JP7095992B2 JP7095992B2 (ja) | 2022-07-05 |
Family
ID=56108081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530141A Active JP7095992B2 (ja) | 2014-12-08 | 2015-12-08 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (enExample) |
| EP (1) | EP3230311B1 (enExample) |
| JP (2) | JP7095992B2 (enExample) |
| KR (1) | KR102654033B1 (enExample) |
| CN (1) | CN107108718B (enExample) |
| AU (1) | AU2015360642B2 (enExample) |
| CA (1) | CA2968987C (enExample) |
| NZ (1) | NZ732073A (enExample) |
| RU (1) | RU2725807C2 (enExample) |
| SG (1) | SG11201704124YA (enExample) |
| WO (1) | WO2016094456A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| JP7095992B2 (ja) | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP7748944B2 (ja) * | 2020-06-30 | 2025-10-03 | 株式会社ガイアバイオメディシン | Ｎｋ細胞と抗体との結合を安定化する方法、及びその利用 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| PL195870B1 (pl) * | 1998-08-11 | 2007-11-30 | Biogen Idec Inc | Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny |
| ES2311560T3 (es) * | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| US7786279B2 (en) * | 2003-02-27 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection |
| AU2004245038A1 (en) * | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| ZA200601699B (en) * | 2003-10-16 | 2007-05-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
| BRPI0507649A (pt) * | 2004-02-16 | 2007-07-10 | Micromet Ag | molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| CA2676098A1 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble fcgammaria and related methods |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| CA2824279A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
| WO2013086636A1 (en) * | 2011-12-15 | 2013-06-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Soluble igf receptor fc fusion proteins and uses thereof |
| ES2680151T3 (es) * | 2012-03-01 | 2018-09-04 | Amgen Research (Munich) Gmbh | Moléculas de unión de polipéptidos de larga duración |
| JP7095992B2 (ja) | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
-
2015
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113710707B (zh) | 结合于psma的重链抗体 | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2021515566A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| Getts et al. | Have we overestimated the benefit of human (ized) antibodies? | |
| JP2020525032A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| JP2016513467A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| JP2022505445A5 (enExample) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2013520984A5 (enExample) | ||
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| WO2022242703A1 (zh) | 抗msln抗体及其应用 |